A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors
about
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancerSafety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.Current controversies in the management of metastatic colorectal cancer.Etirinotecan pegol for the treatment of breast cancer.Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.Camptothecin induces G2/M phase arrest through the ATM-Chk2-Cdc25C axis as a result of autophagy-induced cytoprotection: Implications of reactive oxygen species.Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives.
P2860
Q30358635-87BCB470-3ABD-4080-8CE9-223A98EAB4D4Q34538416-BE8A3BA6-4505-456D-B73D-8E5CE078C79EQ35599716-C3632894-CB69-4030-A1E7-5A664C79366FQ35675340-CECC169F-3A79-42E2-A2C2-59B0ECA2DDB2Q35805489-AD02C707-0CD9-4AD1-9A37-12C2194CBFF9Q37079932-F2F30D07-273E-424A-ACF3-FDD9617E2C03Q37413146-C30813D0-D667-4D40-873D-5B8EB4B01253Q37578351-D756C2C2-734C-4149-A421-AA2AD40E330EQ38091335-2E004A98-82E2-4A51-B030-B264F97D373BQ38180311-51BAE417-1ED2-42C7-A827-DD1C6CC1EEA4Q38527929-00F4BB47-3C3F-4048-A50D-2133CDC752C0Q38538213-E9794B90-D198-4FCB-BA7F-D3A92E5B45C4Q38735361-D5498B30-8A7A-4686-8A5F-D1AA929D650AQ48172134-B926EAB0-49A4-4A8B-8DD1-2553879A3BAEQ54978825-7EDB5150-F8F8-41C4-B926-FD82D9B5F365Q55323463-1025385F-D03D-4C6F-924A-DECCD5EA04FDQ55417928-469B9D3F-4CAF-4A15-8D69-1A1E917382B1
P2860
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A multicenter, phase I, dose-e ...... s with refractory solid tumors
@ast
A multicenter, phase I, dose-e ...... s with refractory solid tumors
@en
type
label
A multicenter, phase I, dose-e ...... s with refractory solid tumors
@ast
A multicenter, phase I, dose-e ...... s with refractory solid tumors
@en
prefLabel
A multicenter, phase I, dose-e ...... s with refractory solid tumors
@ast
A multicenter, phase I, dose-e ...... s with refractory solid tumors
@en
P2093
P2860
P1476
A multicenter, phase I, dose-e ...... s with refractory solid tumors
@en
P2093
Allen Cohn
Carlos Alemany
Daniel D Von Hoff
Erica White
Gayle S Jameson
Glen J Weiss
Ioana Hinshaw
John T Hamm
Katrina Schroeder
Lee S Rosen
P2860
P304
P356
10.1158/1078-0432.CCR-12-1201
P407
P577
2012-11-07T00:00:00Z